Travere Therapeutics, Inc.

How big is Travere Therapeutics, Inc.?

As of Jun 18, Travere Therapeutics, Inc. has a market capitalization of $1.25 billion, with net sales of $273.54 million and a net profit of -$225.90 million over the last four quarters. Shareholder's funds are reported at $59.08 million, and total assets amount to $594.12 million.

As of Jun 18, Travere Therapeutics, Inc. has a market capitalization of 1,250.82 million, which classifies it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 273.54 million, while the sum of net profit for the same period is -225.90 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 59.08 million, and the total assets amount to 594.12 million.

What does Travere Therapeutics, Inc. do?

Travere Therapeutics, Inc. is a micro-cap pharmaceutical and biotechnology company with recent net sales of $82 million and a net loss of $41 million. It has a market cap of approximately $1.25 billion and key metrics indicating significant financial challenges, including a debt-to-equity ratio of 1.91 and a return on equity of -681.59%.

Overview: <BR>Travere Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 82 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -41 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,250.82 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.91 <BR>Return on Equity: -681.59% <BR>Price to Book: 38.11<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Travere Therapeutics, Inc.?

Is Travere Therapeutics, Inc. overvalued or undervalued?

As of November 3, 2016, Travere Therapeutics, Inc. is considered a risky investment due to its overvaluation indicated by a high Price to Book Value of 41.45, negative EV ratios, and significantly negative ROCE and ROE, despite a strong recent stock return that may not be sustainable.

As of 3 November 2016, the valuation grade for Travere Therapeutics, Inc. changed from attractive to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued, as evidenced by a Price to Book Value of 41.45 and negative EV to EBIT and EV to EBITDA ratios of -6.32 and -7.97, respectively. Additionally, the company's ROCE and ROE are significantly negative at -235.78% and -681.59%, highlighting severe operational inefficiencies.<BR><BR>In comparison to peers, Travere's valuation ratios are concerning; for instance, Amneal Pharmaceuticals, Inc. has a P/E ratio of 48.88, while NewAmsterdam Pharma Co. NV shows a P/E of -20.32, both indicating a more favorable valuation landscape. Furthermore, despite a strong 1Y stock return of 68.57% compared to the S&P 500's 17.14%, the long-term performance over 3Y and 5Y shows negative returns for Travere, suggesting that its recent gains may not be sustainable.

Is Travere Therapeutics, Inc. technically bullish or bearish?

As of August 5, 2025, Travere Therapeutics, Inc. shows a mildly bullish trend, supported by positive MACD, Bollinger Bands, and moving averages, despite a bearish weekly RSI and mixed Dow Theory signals.

As of 5 August 2025, the technical trend for Travere Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD and Bollinger Bands are both bullish, while the daily moving averages also indicate a bullish stance. However, the weekly RSI is bearish, and the Dow Theory shows no trend on the weekly but is mildly bullish on the monthly. The stock has performed well over the past month with a return of 28.88%, significantly outperforming the S&P 500's 2.33% return in the same period. Overall, the current technical stance is mildly bullish, driven by strong indicators in the MACD, Bollinger Bands, and moving averages.